(Q77653433)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852160%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

title

Choosing an equivalence limit for noninferiority or equivalence studies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852160%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852160%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

publication date

1 February 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852160%20AND%20SRC:MED&resulttype=core&format=json

Contemporary Clinical Trials

7 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852160%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852160%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852160%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

page(s)

2-14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852160%20AND%20SRC:MED&resulttype=core&format=json

The continuing unethical use of placebo controls

7 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

When are clinical trials of a given agent vs. placebo no longer appropriate or feasible?

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Are placebo-controlled clinical trials ethical or needed when alternative treatment exists?

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

"Proving the null hypothesis" in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Establishing equivalence by showing that a specified percentage of the effect of the active control over placebo is maintained

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Problems in interpreting active control equivalence trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Trials to assess equivalence: the importance of rigorous methods

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Can we reduce the dose of a vaccine?

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

A perspective on the regulation of the evaluation of new antithrombotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Practical issues in equivalence trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Equivalence and noninferiority trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Sample sizes for event rate equivalence trials using prior information.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Clinical and statistical issues in therapeutic equivalence trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

The number needed to treat: a clinically useful measure of treatment effect

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Design and interpretation of equivalence trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Indexes of contrast and quantitative significance for comparisons of two groups

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Some Practical Guidelines for Effective Sample Size Determination

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Generalized treatment effects for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Determining equivalence and the impact of sample size in anti-infective studies: a point to consider

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

On testing equivalence of three populations.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

Design and analysis of three treatment equivalence trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

An alternative to the use of two-sided tests in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

A useful testing strategy in phase III trials: combined test of superiority and test of equivalence

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900196-9

7 January 2021

10.1016/S0197-2456(01)00196-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11852160%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference